Cargando…
Blastocyst transfer does not improve cycle outcome as compared to D3 transfer in antagonist cycles with an elevated progesterone level on the day of hCG
OBJECTIVE: To evaluate the association between progesterone elevation on the day of human chorionic gonadotropin (hCG) administration and clinical pregnancy rates of gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles with the tr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590209/ https://www.ncbi.nlm.nih.gov/pubmed/28890427 http://dx.doi.org/10.4274/jtgga.2017.0012 |
_version_ | 1783262491595243520 |
---|---|
author | Demirel, Cem Aydoğdu, Serkan Özdemir, Arzu İlknur Keskin, Gülşah Baştu, Ercan Buyru, Faruk |
author_facet | Demirel, Cem Aydoğdu, Serkan Özdemir, Arzu İlknur Keskin, Gülşah Baştu, Ercan Buyru, Faruk |
author_sort | Demirel, Cem |
collection | PubMed |
description | OBJECTIVE: To evaluate the association between progesterone elevation on the day of human chorionic gonadotropin (hCG) administration and clinical pregnancy rates of gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles with the transfer of embryos at different developmental stages (day-3 versus day-5 ETs). MATERIAL AND METHODS: This is a retrospective analysis of fresh IVF/ICSI; 194 cycles out of 2676 conducted in a single center. RESULTS: A total of 2676 cycles were analyzed, of which 386 had no progesterone measurements available. Two hundred eighteen cycles had progesterone elevation (p>1.5 ng/mL) giving an overall incidence of 9.5%. Twenty-four cycles were excluded from further analysis. Of the remaining 194 cycles, 151 had day-3 transfers and 43 had blastocyst transfers. There was no statistically significant difference in pregnancy and clinical pregnancy rates per transfer between the D3-ET and D5-ET groups (46% vs. 49%, and 39% vs. 35%, respectively). CONCLUSION: The results of this study suggest that blastocyst transfer does not improve cycle outcomes compared with D3 transfer in GnRH antagonist cycles with an elevated progesterone level on the day of hCG. |
format | Online Article Text |
id | pubmed-5590209 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-55902092017-09-13 Blastocyst transfer does not improve cycle outcome as compared to D3 transfer in antagonist cycles with an elevated progesterone level on the day of hCG Demirel, Cem Aydoğdu, Serkan Özdemir, Arzu İlknur Keskin, Gülşah Baştu, Ercan Buyru, Faruk J Turk Ger Gynecol Assoc Original Investigation OBJECTIVE: To evaluate the association between progesterone elevation on the day of human chorionic gonadotropin (hCG) administration and clinical pregnancy rates of gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles with the transfer of embryos at different developmental stages (day-3 versus day-5 ETs). MATERIAL AND METHODS: This is a retrospective analysis of fresh IVF/ICSI; 194 cycles out of 2676 conducted in a single center. RESULTS: A total of 2676 cycles were analyzed, of which 386 had no progesterone measurements available. Two hundred eighteen cycles had progesterone elevation (p>1.5 ng/mL) giving an overall incidence of 9.5%. Twenty-four cycles were excluded from further analysis. Of the remaining 194 cycles, 151 had day-3 transfers and 43 had blastocyst transfers. There was no statistically significant difference in pregnancy and clinical pregnancy rates per transfer between the D3-ET and D5-ET groups (46% vs. 49%, and 39% vs. 35%, respectively). CONCLUSION: The results of this study suggest that blastocyst transfer does not improve cycle outcomes compared with D3 transfer in GnRH antagonist cycles with an elevated progesterone level on the day of hCG. Galenos Publishing 2017-09 2017-09-01 /pmc/articles/PMC5590209/ /pubmed/28890427 http://dx.doi.org/10.4274/jtgga.2017.0012 Text en ©Copyright 2017 by the Turkish-German Gynecological Education and Research Foundation http://creativecommons.org/licenses/by/2.5/ Journal of the Turkish-German Gynecological Association |
spellingShingle | Original Investigation Demirel, Cem Aydoğdu, Serkan Özdemir, Arzu İlknur Keskin, Gülşah Baştu, Ercan Buyru, Faruk Blastocyst transfer does not improve cycle outcome as compared to D3 transfer in antagonist cycles with an elevated progesterone level on the day of hCG |
title | Blastocyst transfer does not improve cycle outcome as compared to D3 transfer in antagonist cycles with an elevated progesterone level on the day of hCG |
title_full | Blastocyst transfer does not improve cycle outcome as compared to D3 transfer in antagonist cycles with an elevated progesterone level on the day of hCG |
title_fullStr | Blastocyst transfer does not improve cycle outcome as compared to D3 transfer in antagonist cycles with an elevated progesterone level on the day of hCG |
title_full_unstemmed | Blastocyst transfer does not improve cycle outcome as compared to D3 transfer in antagonist cycles with an elevated progesterone level on the day of hCG |
title_short | Blastocyst transfer does not improve cycle outcome as compared to D3 transfer in antagonist cycles with an elevated progesterone level on the day of hCG |
title_sort | blastocyst transfer does not improve cycle outcome as compared to d3 transfer in antagonist cycles with an elevated progesterone level on the day of hcg |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590209/ https://www.ncbi.nlm.nih.gov/pubmed/28890427 http://dx.doi.org/10.4274/jtgga.2017.0012 |
work_keys_str_mv | AT demirelcem blastocysttransferdoesnotimprovecycleoutcomeascomparedtod3transferinantagonistcycleswithanelevatedprogesteronelevelonthedayofhcg AT aydogduserkan blastocysttransferdoesnotimprovecycleoutcomeascomparedtod3transferinantagonistcycleswithanelevatedprogesteronelevelonthedayofhcg AT ozdemirarzuilknur blastocysttransferdoesnotimprovecycleoutcomeascomparedtod3transferinantagonistcycleswithanelevatedprogesteronelevelonthedayofhcg AT keskingulsah blastocysttransferdoesnotimprovecycleoutcomeascomparedtod3transferinantagonistcycleswithanelevatedprogesteronelevelonthedayofhcg AT bastuercan blastocysttransferdoesnotimprovecycleoutcomeascomparedtod3transferinantagonistcycleswithanelevatedprogesteronelevelonthedayofhcg AT buyrufaruk blastocysttransferdoesnotimprovecycleoutcomeascomparedtod3transferinantagonistcycleswithanelevatedprogesteronelevelonthedayofhcg |